Cargando…

Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy

INTRODUCTION: Radionuclide bone scan (BS) used to be the investigation of choice for detecting osseous metastases in prostate cancer. Now, with the availability serum prostate specific antigen (PSA) testing, clinicians do have a timely, cost-effective method to determine those patients who are highl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamaleshwaran, Koramadai Karuppusamy, Mittal, Bhagwant Rai, Harisankar, Chidambaram Natrajan Balasubramanian, Bhattacharya, Anish, Singh, Shrawan Kumar, Mandal, Arup K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665151/
https://www.ncbi.nlm.nih.gov/pubmed/23723577
http://dx.doi.org/10.4103/0972-3919.110683
_version_ 1782271218583339008
author Kamaleshwaran, Koramadai Karuppusamy
Mittal, Bhagwant Rai
Harisankar, Chidambaram Natrajan Balasubramanian
Bhattacharya, Anish
Singh, Shrawan Kumar
Mandal, Arup K
author_facet Kamaleshwaran, Koramadai Karuppusamy
Mittal, Bhagwant Rai
Harisankar, Chidambaram Natrajan Balasubramanian
Bhattacharya, Anish
Singh, Shrawan Kumar
Mandal, Arup K
author_sort Kamaleshwaran, Koramadai Karuppusamy
collection PubMed
description INTRODUCTION: Radionuclide bone scan (BS) used to be the investigation of choice for detecting osseous metastases in prostate cancer. Now, with the availability serum prostate specific antigen (PSA) testing, clinicians do have a timely, cost-effective method to determine those patients who are highly unlikely to have osseous metastases. We determine the utility of PSA for predicting the presence of skeletal metastasis on BSs in prostate cancer patients. MATERIALS AND METHODS: Retrospective analysis of medical records of 322 consecutive prostate cancers patients subjected to BS during the last 3 years was done. 52 cases were excluded due to following reasons: Serum PSA not available, hormonal or other therapy given prior to serum PSA measurement, and/or BS, and symptomatic for bone metastasis. In remaining 270 cases, PSA value and BS were evaluated. BS was performed with Tc99m methylene diphosphonate (MDP) as per the standard protocol. RESULTS: BS was found to be positive in 153/270 (56%) and negative in 117 (46%) patients. Of the 153 positive cases, 108 (70%) had serum PSA > 100 ng/ml, 42 (28%) had PSA of 20-100 ng/ml and only 3 (2%) had PSA < 20 ng/ml. All the patients with PSA > 100 ng/ml had multiple skeletal metastasis. Of the 117 negative cases, 110 (94%) had a PSA < 20 ng/ml, 5 had between 20 and 100 ng/ml and only 2 (1.8%) had PSA > 100 ng/ml. Of the 113 patients with serum PSA < 20 ng/ml, 110 (97.4%) did not show any bony metastasis. 150/157 (95.5%) patients with PSA > 20 ng/ml had bone metastasis. Using this criterion, 110 (40.7%) scans would have been omitted. CONCLUSIONS: Serum PSA < 20 ng/ml have high predictive value in ruling out skeletal metastasis. Our data are in corroboration with results from previous studies that BS should be performed only if PSA > 20 ng/ml. Using this cut-off, unnecessary investigation can be avoided. Avoiding BS in this group of patients would translate into a significant cost-saving and reduction in their psychological and physical burden.
format Online
Article
Text
id pubmed-3665151
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-36651512013-05-30 Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy Kamaleshwaran, Koramadai Karuppusamy Mittal, Bhagwant Rai Harisankar, Chidambaram Natrajan Balasubramanian Bhattacharya, Anish Singh, Shrawan Kumar Mandal, Arup K Indian J Nucl Med Original Article INTRODUCTION: Radionuclide bone scan (BS) used to be the investigation of choice for detecting osseous metastases in prostate cancer. Now, with the availability serum prostate specific antigen (PSA) testing, clinicians do have a timely, cost-effective method to determine those patients who are highly unlikely to have osseous metastases. We determine the utility of PSA for predicting the presence of skeletal metastasis on BSs in prostate cancer patients. MATERIALS AND METHODS: Retrospective analysis of medical records of 322 consecutive prostate cancers patients subjected to BS during the last 3 years was done. 52 cases were excluded due to following reasons: Serum PSA not available, hormonal or other therapy given prior to serum PSA measurement, and/or BS, and symptomatic for bone metastasis. In remaining 270 cases, PSA value and BS were evaluated. BS was performed with Tc99m methylene diphosphonate (MDP) as per the standard protocol. RESULTS: BS was found to be positive in 153/270 (56%) and negative in 117 (46%) patients. Of the 153 positive cases, 108 (70%) had serum PSA > 100 ng/ml, 42 (28%) had PSA of 20-100 ng/ml and only 3 (2%) had PSA < 20 ng/ml. All the patients with PSA > 100 ng/ml had multiple skeletal metastasis. Of the 117 negative cases, 110 (94%) had a PSA < 20 ng/ml, 5 had between 20 and 100 ng/ml and only 2 (1.8%) had PSA > 100 ng/ml. Of the 113 patients with serum PSA < 20 ng/ml, 110 (97.4%) did not show any bony metastasis. 150/157 (95.5%) patients with PSA > 20 ng/ml had bone metastasis. Using this criterion, 110 (40.7%) scans would have been omitted. CONCLUSIONS: Serum PSA < 20 ng/ml have high predictive value in ruling out skeletal metastasis. Our data are in corroboration with results from previous studies that BS should be performed only if PSA > 20 ng/ml. Using this cut-off, unnecessary investigation can be avoided. Avoiding BS in this group of patients would translate into a significant cost-saving and reduction in their psychological and physical burden. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3665151/ /pubmed/23723577 http://dx.doi.org/10.4103/0972-3919.110683 Text en Copyright: © Indian Journal of Nuclear Medicine http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kamaleshwaran, Koramadai Karuppusamy
Mittal, Bhagwant Rai
Harisankar, Chidambaram Natrajan Balasubramanian
Bhattacharya, Anish
Singh, Shrawan Kumar
Mandal, Arup K
Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy
title Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy
title_full Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy
title_fullStr Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy
title_full_unstemmed Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy
title_short Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy
title_sort predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665151/
https://www.ncbi.nlm.nih.gov/pubmed/23723577
http://dx.doi.org/10.4103/0972-3919.110683
work_keys_str_mv AT kamaleshwarankoramadaikaruppusamy predictivevalueofserumprostatespecificantigenindetectingbonemetastasisinprostatecancerpatientsusingbonescintigraphy
AT mittalbhagwantrai predictivevalueofserumprostatespecificantigenindetectingbonemetastasisinprostatecancerpatientsusingbonescintigraphy
AT harisankarchidambaramnatrajanbalasubramanian predictivevalueofserumprostatespecificantigenindetectingbonemetastasisinprostatecancerpatientsusingbonescintigraphy
AT bhattacharyaanish predictivevalueofserumprostatespecificantigenindetectingbonemetastasisinprostatecancerpatientsusingbonescintigraphy
AT singhshrawankumar predictivevalueofserumprostatespecificantigenindetectingbonemetastasisinprostatecancerpatientsusingbonescintigraphy
AT mandalarupk predictivevalueofserumprostatespecificantigenindetectingbonemetastasisinprostatecancerpatientsusingbonescintigraphy